Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Unmet Needs: Sequencing After Immunotherapy in NSCLC

July 13th 2017

Questions Surrounding Therapeutic Sequencing for NSCLC

July 13th 2017

Immunotherapy for Relapsed/Refractory NSCLC

July 13th 2017

Early Experience; Immunotherapy + Chemotherapy for NSCLC

July 13th 2017

Upfront Immunotherapy + Chemotherapy for NSCLC

July 13th 2017

Upfront Immunotherapy for NSCLC

July 13th 2017

The Ever-Evolving Treatment Paradigm for NSCLC

July 13th 2017

Dr. Klein on Precision Medicine for Prostate Cancer

July 13th 2017

Eric Klein, MD, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses precision medicine in patients with prostate cancer.

Study Offers Insight Into Age-Specific Breast, Ovarian Cancer Risk for BRCA-Positive Women

June 27th 2017

Researchers have yet to determine the degree to which harboring a BRCA1 or BRCA2 mutation raises a woman’s lifetime risk of developing breast and ovarian cancer.

Evolving Therapies in HR+ Metastatic Breast Cancer

June 16th 2017

Options With CDK4/6 in HR+ Metastatic Breast Cancer

June 16th 2017

Final Thoughts on Progress in Breast Cancer Research

June 16th 2017

Immunotherapy for Triple-Negative Breast Cancer

June 16th 2017

PARP Inhibitors for BRCA-Mutated TNBC

June 16th 2017

BRCA-Mutated Triple-Negative Breast Cancer

June 16th 2017

Metastatic Triple-Negative Breast Cancer

June 16th 2017

Brain Metastases in HER2-Positive Breast Cancer

June 16th 2017

Triple-Positive Metastatic Breast Cancer

June 16th 2017

Adjuvant Therapy for High-Risk HER2+ Breast Cancer

June 16th 2017

Pending FDA Approval of Neratinib in HER2+ Breast Cancer

June 16th 2017